Niki BioSolutions (NIKI) EBIT Margin (2024)
Niki BioSolutions (NIKI) reported EBIT Margin of -293.17% for FY2025.
Powered by 
Analysis
Niki BioSolutions (NIKI) EBIT Margin (2024) Analysis & Trends
Dating back to FY2022, Niki BioSolutions' EBIT Margin record includes 4 years.
- EBIT Margin has a three-year change of -1750.47 percentage points (FY2022 to FY2025).
- According to Business Quant data, EBIT Margin came in at -34.21% in FY2024, 2588.49% in FY2023 (+1131.19 pp) and 1457.31% in FY2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,172.40 Bn | 1,140.99 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 642.90 Bn | 561.42 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 502.02 Bn | 475.14 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 375.88 Bn | 330.26 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 302.81 Bn | 266.80 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 268.58 Bn | 242.27 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 242.38 Bn | 197.78 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 193.63 Bn | 167.83 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 172.59 Bn | 119.24 Bn | 10.94 Bn | 28.37% |
| 10 | Niki BioSolutions | 987,011.07 | 746,696.07 | - | - |
API Access
Niki BioSolutions EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=NIKI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "NIKI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=NIKI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();